Hyperactivity Disorder Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Hyperactivity Disorder stocks.

Hyperactivity Disorder Stocks Recent News

Date Stock Title
Apr 30 LLY Eli Lilly in charts: Mounjaro, Zepbound, Verzenio, and Jardiance drive revenue growth in Q1; Trulicity declines 26%
Apr 30 LLY Eli Lilly Non-GAAP EPS of $2.58 beats by $0.09, revenue of $8.77B misses by $160M
Apr 30 LLY Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum
Apr 30 LLY Chasing Novo and Lilly: The obesity drugs that could challenge Wegovy and Zepbound
Apr 29 LLY Why these analysts are bullish on healthcare stocks
Apr 29 LLY All Eyes Are on Zepbound Sales as Lilly Reports Earnings
Apr 29 LLY How expanded use of GLP-1s could affect long-term outlooks for Eli Lilly and Novo Nordisk
Apr 29 LLY Eli Lilly Q1 Earnings Preview: Weight loss therapies to drive quarterly growth
Apr 29 LLY UPDATE 2-One dose of Novo Nordisk's Wegovy back in supply, FDA website shows
Apr 29 LLY Here's How Much Stock Eli Lilly Repurchased in 2023
Apr 29 COLL Collegium enters authorized generic agreement with Hikma for Nucynta franchise
Apr 29 LLY Novo Nordisk: Growth Is Still A Better Choice
Apr 29 COLL Collegium (COLL) to Report Q1 Earnings: Here's What to Expect
Apr 29 LLY How To Earn $500 A Month From Eli Lilly Stock Ahead Of Q1 Earnings Report
Apr 29 COLL Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER
Apr 29 LLY Pipeline Moves: Investigator-led trial of Lilly’s merestinib in solid tumours terminated
Apr 29 LLY Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
Apr 28 LLY Eli Lilly Just Announced More Good News: Time to Buy?
Apr 28 LLY What do weight-loss drugs mean for the diet industry?
Apr 27 LLY Forget Nvidia, These Unstoppable Stocks Are Better Buys
Hyperactivity Disorder

Attention deficit hyperactivity disorder (ADHD) is a mental disorder of the neurodevelopmental type. It is characterized by difficulty paying attention, excessive activity, or difficulty controlling behavior which is not appropriate for a person's age. The symptoms appear before a person is twelve years old, are present for more than six months, and may cause problems in at least two settings (such as school, home, or recreational activities). In children, problems paying attention may result in poor school performance. Additionally there is an association with other mental disorders and substance misuse. Although it causes impairment, particularly in modern society, many people with ADHD can have sustained attention span for tasks they find interesting or rewarding (known as hyperfocus).Despite being the most commonly studied and diagnosed mental disorder in children and adolescents, the exact cause is unknown in the majority of cases. It affects about 5–7% of children when diagnosed via the DSM-IV criteria and 1–2% when diagnosed via the ICD-10 criteria. As of 2015 it is estimated to affect about 51.1 million people globally. Rates are similar between countries and depend mostly on how it is diagnosed. ADHD is diagnosed approximately two times more often in boys than in girls, although the disorder is often overlooked in girls because their symptoms differ from those of boys. About 30–50% of people diagnosed in childhood continue to have symptoms into adulthood and between 2–5% of adults have the condition. In adults inner restlessness rather than hyperactivity may occur. The condition can be difficult to tell apart from other conditions, as well as to distinguish from high levels of activity that are still within the range of normative behaviors.ADHD management recommendations vary by country and usually involve some combination of counseling, lifestyle changes, and medications. The British guideline only recommends medications as a first-line treatment in children who have severe symptoms and for medication to be considered in those with moderate symptoms who either refuse or fail to improve with counseling, though for adults medications are a first-line treatment. Canadian and American guidelines recommend that medications and behavioral therapy be used together as a first-line therapy, except in preschool-aged children. Stimulant medication therapy is not recommended as a first-line therapy in preschool-aged children in either guideline. Treatment with stimulants is effective for at least 14 months; however, their long term effectiveness is unclear. Adults often develop coping skills which make up for some or all of their impairments.The medical literature has described symptoms similar to those of ADHD since the 18th century. ADHD, its diagnosis, and its treatment have been considered controversial since the 1970s. The controversies have involved clinicians, teachers, policymakers, parents, and the media. Topics include ADHD's causes and the use of stimulant medications in its treatment. Most healthcare providers accept ADHD as a genuine disorder in children and adults, and the debate in the scientific community mainly centers on how it is diagnosed and treated. The condition was officially known as attention-deficit disorder (ADD) from 1980 to 1987, while before this it was known as hyperkinetic reaction of childhood.

Browse All Tags